Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study (European Urology)

In men undergoing radical prostatectomy for clinically localized high-risk prostate cancer, adjuvant docetaxel chemotherapy did not lead to statistically significant improvement in progression-free survival, although prespecified subgroup analyses suggest potential benefit for patients with Gleason grade =pT3b pathology.